

## **News Release**

September 11, 2007

## Notice of Completion of Acquisition of the Company's Own Shares

Japan, September 11, 2007 --- Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced that it completed acquisition of its own shares in the market, which was resolved by its Board of Directors on August 28, 2007.

**Particulars** 

1. Class of shares acquired: Common stock of the Company

2. Period of acquisition: From August 29, 2007 to September 10, 2007

3. Total number of shares acquired: 8.3 million shares

4. Total value of acquisition: ¥ 43,088,442,000

5. Method of acquisition: Purchased on the Tokyo Stock Exchange and through

ToSTNeT-2 (closing price transaction)

(Reference)

Resolution of the Board of Directors on August 28, 2007

1. Reasons for acquisition of its own shares: In order to improve capital efficiency and enhance returns to

shareholders

2.Class of shares to be acquired: Common stock of the Company

3 Number of shares to be acquired: 8.3 million shares (maximum)

(equivalent to 1.60% of a total of issued shares)

4. Aggregate amount of acquisition cost: ¥ 45 billion (maximum)

5. Period of acquisition: From August 29, 2007 to September 20, 2007

######

Contacts for inquiries or additional information

Astellas Pharma Inc.

**Corporate Communications** 

Tel: +81-3-3244-3201 Fax: +81-3-5201-7473

http://www.astellas.com